<ul data-eligibleForWebStory="false"><li>Wockhardt, a drug firm, has announced its exit from the US generic business due to continuous losses.</li><li>The company will shift its focus to new drug discovery in antibiotics and biological drugs for diabetes.</li><li>Wockhardt aims to enhance its advanced product portfolio by concentrating on antibiotic drug discovery and its biological portfolio in Insulin.</li><li>The decision to exit the US generic business comes after incurring significant losses, leading to voluntary liquidation under Chapter 7 of the US Bankruptcy Code for its American subsidiaries.</li></ul>

Wockhardt To Exit US Generic Business; Focus On Antibiotics, Diabetes Care

Discover more